Abstract:Abstract Background: ARX788 is a novel site-specific antibody drug conjugate (ADC) that consists of a human epidermal growth factor receptor 2 (HER2) targeting monoclonal antibody (mAb) linked to the cytotoxic payload AS269, a highly potent tubulin inhibitor. Through a proprietary technology, a non-natural amino acid is precisely incorporated into the pre-determined site on the heavy chain of the mAb, and AS269 is specifically conjugated to the non-natural amino acid. In the first-in-human study in Australia/New Zealand (NCT02512237), delayed drug-induced pneumonitis, which occurred after 4-5 cycles of administration, were observed in participants at dose levels of 1.3 mg/kg Q3W or higher. Here, we present results of a phase I study (CTR20171162) to evaluate safety, pharmacokinetics, and preliminary antitumor effect of ARX788 in Chinese patients with metastatic HER2-positive breast cancer, with special focus on the delayed pneumonitis. Methods: Patients with metastatic HER2-positive breast cancer received intravenous ARX788 at doses of 0.33, 0.66, 0.88, 1.1, 1.3, 1.5 mg/kg Q3W or 0.88, 1.1, 1.3 mg/kg Q4W. The DLT assessment period was set to be 21 days in 0.33, 0.66 mg/kg Q3W cohorts, and additional 63 days (total 84 days) in other dose cohorts for the pulmonary toxicity. Dose cohorts were expanded at 1.1 and 1.3 mg/kg Q3W. Safety and tolerability were assessed by monitoring adverse events (AEs) and antitumor effects were evaluated according to the RECIST v1.1 criteria. Pulmonary toxicity of special interest was assessed every 2 cycles of therapy by CT imaging. Serum concentrations of ARX788 ADC, total antibody, and metabolite pAF-AS269 were measured and PK parameters were calculated. Results: As of 3 July 2019, 45 female Chinese participants with age range from 30 to 67 received ARX788, with 31 of whom had been treated for at least 84 days. No dose-limiting toxicities and treatment-related serious adverse events were observed. Serious blood and liver toxicity that are commonly associated with ADCs were rarely observed (only one participant experienced Grade 4 neutrophil count decreased on cycle 18 and none for ≥Grade 3 liver toxicity). Adverse events that required special attentions were ocular and pulmonary toxicity. Ocular events were mostly mild to moderate in severity and were reversible. Three participants experienced Grade 2 drug-related pneumonitis observed on days 130, 172 and 224, all of whom resolved after steroid treatment and re-started ARX788 treatment with dose reduction. ARX788 ADC serum exposure increased with dose increment and the mean terminal phase half-life ranged between 2.3 and 4.9 days. Among 42 evaluated participants, the overall response rate was 31% (13/42) and 42% (5/12) in 1.3 mg/kg Q3W cohort. One participant in 0.88 mg/kg Q3W cohort has undergone the treatment for more than 17 months. Conclusions: ARX788 was well tolerated in heavily-pretreated patients with HER2-positive metastatic breast cancer without evidence of Grade 3 or greater pneumonitis. Encouraging overall response rate was observed in 1.3 mg/kg Q3W cohort. Considering the predicted benefit/risk profile, 1.3 mg/kg Q3W is the recommended dose for further development of ARX788 in HER2-positive breast cancer. Citation Format: Xichun Hu, Jian Zhang, Dongmei Ji, Gang Xia, Yanping Ji, Gaozhun Xiong, Xuejun Liang. A phase 1 study of ARX788, a HER2-targeting antibody-drug conjugate, in patients with metastatic HER2-positive breast cancer [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P1-18-16.

Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in phase I clinical trial

Tumor vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid inhibits platelet activation and thrombosis via inhibition of thromboxane A2 signaling and phosphodiesterase

Dissection of stromal and cancer cell-derived signals in melanoma xenografts before and after treatment with DMXAA

First-in-human, Phase I Study of AK109, an Anti-Vegfr2 Antibody in Patients with Advanced or Metastatic Solid Tumors

Abstract A139: Preclinical characterization and prediction of human pharmacokinetics and efficacious dose for VIP236, a novel alpha V beta 3 binding small molecule-drug conjugate (SMDC)

Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody-drug Conjugate Targeting AXL-expressing Cancers

Safety and unique pharmacokinetic profile of ARX788, a site-specific ADC, in heavily pretreated patients with HER2-overexpresing solid tumors: Results from two phase 1 clinical trials.

Preclinical factors influencing the relative contributions of Phase I and II enzymes to the metabolism of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid

A First-in-human, Phase I, Dose-Escalation Study to Evaluate Pharmacokinetics, Safety, and Tolerability of KD6001, a Novel Anti-Ctla-4 Monoclonal Antibody (mab) in Patients with Advanced Solid Tumors.

The use of pharmacokinetic and pharmacodynamic end points to determine the dose of AQ4N, a novel hypoxic cell cytotoxin, given with fractionated radiotherapy in a phase I study.

Abstract CT211: A phase 1 dose-escalation and dose-expansion study to evaluate the safety, pharmacokinetics, and anti- tumor activity of ARX517 in subjects with advanced solid tumors resistant or refractory to standard therapies (APEX-01 trial, NCT04662580)

Characterization of AST‐001 non‐clinical pharmacokinetics: A novel selective AKR1C3‐activated prodrug in mice, rats, and cynomolgus monkeys

Pharmacokinetic Consideration of Venetoclax in Acute Myeloid Leukemia Patients: A Potential Candidate for TDM? A Short Communication

Abstract CT291: A phase 1/2, first-in-human study of DS-3939a in patients with advanced solid tumors: A new DXd ADC targeting TA-MUC1

Development of an LC-MS/MS method for quantifying ASK120067, a novel mutant-selective inhibitor of the epidermal growth factor receptor (EGFR) as well as its main metabolite in human plasma and its application in a pharmacokinetic study

Abstract 1902: ADRX-0706 Nectin-4 antibody-drug conjugate PK/PD characterization elucidates its widened therapeutic window

Use of photoacoustic imaging for monitoring vascular disrupting cancer treatments

Abstract CT140: A phase 1 study of the IAP inhibitor xevinapant (Debio 1143) to evaluate food effect and drug-drug interactions with a proton pump inhibitor in healthy volunteers

Abstract P1-18-16: A Phase 1 Study of ARX788, a HER2-targeting Antibody-Drug Conjugate, in Patients with Metastatic HER2-positive Breast Cancer

Abstract 742: PYX-201, a stroma-targeting ADC composed of an anti-EDB+FN antibody conjugated to Auristatin0101, demonstrates strong anti-tumor efficacy across multiple human cancer indications in pre-clinical PDX tumor models

Abstract 1750: Design and development of a novel highly sequence-selective guanine mono-alkylating DNA-interactive ADC payload suitable for solid tumor treatments